| Name | Title | Contact Details |
|---|
Codan US Corporation is a Santa Ana, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Biomatrix, Inc., together with its subsidiaries in Canada, Europe and Asia, develops, manufactures, markets and sells a series of proprietary viscoelastic products called hylans that are used in therapeutic medical applications and skin care. Hylans are
Amedica Corporation is ISO 13485 certified, and its products are FDA and CE approved. Amedica Corporation is an emerging orthopaedic implant company focused on using its silicon nitride ceramic technologies to develop and commercialize a broad range of innovative, unique spine and total joint implants for the growing orthopaedic device market.
Mission Canon Medical Systems USA delivers innovative imaging solutions and services through our Made for Life philosophy to improve the quality of life for all people. Our Heritage Canon Medical Systems is born from two global leaders—Canon and Toshiba Medical. In business for more than 100 years` Toshiba Medical was built to improve the quality of life for all people. It delivered on this mission with medical innovations that are Made for Life—made to improve the lives of patients` clinicians and administrators. Its legacy was built with pioneering medical technology` such as the world`s first X-ray machines in 1932 and Japan`s first Magnetic Resonance Imaging systems (MRI) in 1983. Toshiba Medical`s vision was strengthened in 2016 with its acquisition by Canon. Canon entered the healthcare business in 1940 with the development of Japan`s first indirect X-ray camera which was used for the early detection of pulmonary tuberculosis. The partnership of these two companies (now Canon Medical Systems Corporation)` brings together two cutting-edge technology businesses` founded with similar values of creativity` flexibility and patient-friendly healthcare solutions. Today` their combined history of research and innovation drive forward Canon Medical Systems` vision for building a world-class healthcare enterprise.
ValenTx was founded with the goal of treating some of the most pervasive health problems of our time: obesity and obesity-related metabolic disorders such as type-2 diabetes and hypertension. Our approach is to create a non-surgical, endoluminal bypass device that builds on the success of established medical interventions, resulting in a highly effective and least-invasive therapy. Current treatments for these diseases include surgery, pharmacology, and medically supervised lifestyle management. The risks, costs, and in some cases poor efficacy of these treatments have hampered their broad adoption by patients, physicians, and payers alike. A truly unmet clinical need exists for a therapy that can deliver the efficacy obtained through surgery, but without the risks and costs associated with surgical intervention. The ValenTx endoluminal bypass therapy mimics the attributes of a Roux-en-Y gastric bypass and is implanted through a non-surgical, endoscopic procedure. This procedure does not require gastric stapling or permanent changes to the patient`s anatomy. The device is removable, replaceable and designed so that the physician could change the therapeutic profile, thereby optimizing the treatment towards the individual patient`s needs. ValenTx has developed a strong intellectual property portfolio, which lies at the foundation of this therapy. The company has successfully conducted a series of clinical studies demonstrating the viability, safety, and efficacy of the therapy.